awmsg logo



eslicarbazepine acetate (Zebinix®)


Reference No. 611

Publication date:
13/11/2012


Last review date:
30/08/2016

Appraisal information

eslicarbazepine acetate (Zebinix®) 800 mg tablet


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 05/09/2012
AWMSG meeting date: 17/10/2012
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 3512
Ministerial ratification: 09/11/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Eslicarbazepine acetate (Zebinix®) is recommended as an option for restricted use within NHS Wales. Eslicarbazepine acetate (Zebinix®) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations, within its licensed indication as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation. Eslicarbazepine acetate (Zebinix®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download